Psoriasis is a chronic immune-mediated inflammatory skin

disease, with one of its incidence peaks occurring during the

reproductive years, including pregnant women. Immunological and

hormonal changes during pregnancy may influence the course of

psoriasis, leading to improvement, worsening, or no change in disease

activity. Conversely, psoriasis itself may affect pregnancy and fetal

outcomes.

Management

of psoriasis during pregnancy requires special consideration, as

several commonly used systemic therapies are contraindicated. This

review summarizes current evidence regarding the course of psoriasis

during pregnancy, associated maternal and fetal outcomes, and

therapeutic management. The aim is to support clinicians in

optimizing disease control while minimizing risks to both the mother

and the fetus and maintaining quality of life.